LONDON (Alliance News) - Amryt Pharma PLC on Monday said its cholesterol reducing drug, Lojuxta, has been approved by the NHS in England.
The pharmaceutical company, which focuses on rare and orphan diseases, said that Lojuxta has been approved for use in adult patients with a disorder that prevents their bodies from removing cholesterol from their blood.
The condition is known as Homozygous Familial Hypercholesterolaemia and causes high cholesterol levels from birth onwards, often causing heart attacks and strokes in very young patients.
Amryt has an exclusive license to sell Lojuxta across a number of places including the European Union, the Middle East, Sizerland, North Africa, Israel, Turkey and Russia.
"This decision today is in line with our strategy to make Lojuxta available to more patients across Amryt's territories and it is estimated that funding approval will have a positive impact on revenue from 2019 and beyond," said Amryt Chief Executive Officer Joe Wiley.
Shares in Amryt were up 0.6% at 16.20 pence on Monday.
